Clinical Trials
Enrolling Trials
11-20 of 21
E2906, Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Bseiso, Ali W
Blood - AML - Acute Myelogenous
Adult
This randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective in treating acute myeloid leukemia.
Spindler, Marilyn K
(715) 387-9444
Lakeview Medical Center
1700 West Stout Street
Rice Lake, WI 54868
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI 54481
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI 54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI 54868
Sacred Heart Hospital (Eau Claire)
900 W Clairemont Ave
Eau Claire, WI 54701
St. Clare's (Weston)
3400 Ministry Parkway
Weston, WI 54476
Weston Center
3501 CRANBERRY BLVD
WESTON, WI 54476
E4512, A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Onitilo, Adedayo A
Lung - Lung
Adult
This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Tumors with this mutation may respond to treatments that target the mutation, such as crizotinib. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. It is not yet known if crizotinib may be an effective treatment for treating non-small cell lung cancer with an ALK fusion mutation.
Bulgrin, Angela M
(715) 221-7261
E7208, A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Islam, Rezwan
Stomach, Intestine, Gut - Rectum
Adult
The primary objectives are: To evaluate the Progression Free Survival (PFS) for the addition of the anti-angiogenic antibody, Ramucirumab, in combination with irinotecan and cetuximab as second line therapy for patients with K-ras wild-type colorectal cancer, as compared to the patients without the antibody. To evaluate the Response Rate for irinotecan, cetuximab and Ramucirumab in this patient population. To evaluate the Grade 3-4 toxicity rates for the combination in this patient population. To evaluate Overall Survival for irinotecan, cetuximab, and ramucirumab in this patient population.
Bulgrin, Angela M
(715) 221-7261
Buttke, Karyn
(715) 387-9149
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
Lakeview Medical Center
1700 West Stout Street
Rice Lake, WI 54868
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI 54449
Marshfield Clinic At James Beck Cancer Center
2251 NORTH SHORE DR
RHINELANDER, WI 54501
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI 54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI 54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI 54868
Weston Center
3501 CRANBERRY BLVD
WESTON, WI 54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
Epidemiology and Clinical Course of Atrial Flutter, Atrial Flutter/Fibrillation and Atrial Fibrillation in the Marshfield Epidemiologic Study Area (MESA)
Vidaillet, Humberto J
Phase I will focus on the incidence and initial course of Artial Flutter & Atrial Flutter/Fibrillation. Phase II will study the incidence of Atrial Fibrillation and will involve study of the long-term clinical course & prevalence of Atrial Flutter, Atrial Flutter/Fibrillation & Atrial Fibrillation.
Beck, Carol M
(715) 389-3144
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI 54449
Marshfield Clinic Research Foundation
1000 N Oak
Marshfield, WI 54449
I4T-MC-JVBT, Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product (IMC-1121B) versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, or Stomach
Stomach, Intestine, Gut - Stomach, Esophagus
Stomach, Intestine, Gut - Gastric
Adult
The primary objective of this study is to assess and compare the progression-free survival (PFS) of patients with advanced adenocarcinoma of the esophagus, gastroesophageal junction GEJ, or stomach receiving mFOLFOX6 with and without ramucirumab DP. The secondary objectives of this study are to compare mFOLFOX6 administered in combination with ramucirumab DP versus mFOLFOX6 with placebo for the following: (safety and toxicity profile, overall survival, objective response rate, time to disease progression, duration of response, assessment of anti-ramucirumab DP antibodies (immunogenicity) and serum levels of ramucirumab DP, assess alterations in circulating angiogenic factors (peripheral blood) during therapy, and assess the association between circulating factor patterns and clinical outcomes, assess the association between tissue-based angiogenesis-related factors and other factors and clinical outcomes, assessment of the potential association between pharmacogenetic markers and clinical outcomes, assessment of plasma angiogenic activity using an ex vivo assay).
Buttke, Karyn
(715) 387-9149
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI 54449
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
NSABP-B-51, A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Wernberg, Jessica A
Breast
Adult
To evaluate whether the addition of chestwall + regional nodal XRT after mastectomy or breast + regional nodal XRT after breast conserving surgery will significantly reduce the rate of events for invasive breast cancer recurrence-free interval (IBC-RFI) in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI 54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI 54868
Sacred Heart Hospital (Eau Claire)
900 W Clairemont Ave
Eau Claire, WI 54701
St. Michaels Hospital
900 Illinois Ave
Stevens Point, WI 54481
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Husak, Michael
Skin
Adult
There are two study questions the investigators are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and flurouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.
S0820, A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers
Islam, Rezwan
Stomach, Intestine, Gut - Rectum
Treatment of Side Effects - Rectum
Treatment of Side Effects
Adult
The purpose of this study is to assess whether the combination of eflornithine 500 mg and sulindac 150 mg (compared to corresponding placebos) has efficacy against colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, any adenomas >/= 0.3 cm, total advanced colorectal events, or total colorectal events.
Franseen, Susan P
(715) 389-4980
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
Marshfield Clinic At James Beck Cancer Center
2251 NORTH SHORE DR
RHINELANDER, WI 54501
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI 54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI 54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI 54868
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI 54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
SPS 3-Genes
Karanjia, Percy N
Neurology - Cerebrovascular Disease
Adult
The primary goal of this study is to collect DNA from participants in SPS3 to understand how variants in the genes of participants affect the SPS3 primary outcome - the prevention of recurrent stroke. The substudy involves the collection of saliva. The study will look at the genes involved in response to drugs, including aspirin and clopidogrel, which are being used in the SPS3 study to prevent repeat stroke and to control blood pressure. The research may help to improve drug therapy who, because of inherited factors, may not otherwise respond well to drugs commonly used to prevent stroke and treat hypertension.
Mancl, Kathleen K
(715) 389-3748
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI 54449
Test
Abboud Leon, Chady
Ovaries, Uterus, Cervix - Ovaries
Adult
TEST
Park Falls Center
50 SHERRY AVE
PARK FALLS, WI 54552